Currently available antiviral treatments have limited efficacy and are threatened by treatment induced and naturally occurring drug resistance, which is of particular concern in the event of severe, life threatening infections.

The influenza nucleoside analog in development by Riboscience, RBS-3165, has the potential to be the most highly efficacious therapy for flu, with broad spectrum activity against all influenza strains, including pandemic (e.g. H1N1 “Swine Flu”) and emergent (e.g. “Bird Flu”) strains.